Correlation Between Acrivon Therapeutics, and Champions Oncology
Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Champions Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Champions Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acrivon Therapeutics, Common and Champions Oncology, you can compare the effects of market volatilities on Acrivon Therapeutics, and Champions Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Champions Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Champions Oncology.
Diversification Opportunities for Acrivon Therapeutics, and Champions Oncology
-0.72 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Acrivon and Champions is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Champions Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Champions Oncology and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Champions Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Champions Oncology has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Champions Oncology go up and down completely randomly.
Pair Corralation between Acrivon Therapeutics, and Champions Oncology
Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to generate 1.65 times more return on investment than Champions Oncology. However, Acrivon Therapeutics, is 1.65 times more volatile than Champions Oncology. It trades about 0.06 of its potential returns per unit of risk. Champions Oncology is currently generating about 0.08 per unit of risk. If you would invest 365.00 in Acrivon Therapeutics, Common on November 3, 2024 and sell it today you would earn a total of 242.00 from holding Acrivon Therapeutics, Common or generate 66.3% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Acrivon Therapeutics, Common vs. Champions Oncology
Performance |
| Timeline |
| Acrivon Therapeutics, |
| Champions Oncology |
Acrivon Therapeutics, and Champions Oncology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Acrivon Therapeutics, and Champions Oncology
The main advantage of trading using opposite Acrivon Therapeutics, and Champions Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Champions Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will offset losses from the drop in Champions Oncology's long position.| Acrivon Therapeutics, vs. Aerovate Therapeutics | Acrivon Therapeutics, vs. Adagene | Acrivon Therapeutics, vs. Rezolute | Acrivon Therapeutics, vs. AN2 Therapeutics |
| Champions Oncology vs. Molecular Partners AG | Champions Oncology vs. MediciNova | Champions Oncology vs. Anebulo Pharmaceuticals | Champions Oncology vs. Shattuck Labs |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Complementary Tools
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |